Drug Profile
Research programme: reduced gastric irritation NSAIDs - Oxford Pharmascience
Alternative Names: OXP 006; OXP 007; OXPzero™ AspirinLatest Information Update: 06 Oct 2017
Price :
$50
*
At a glance
- Originator Oxford Pharmascience
- Class Nonsteroidal anti-inflammatories; Phenylacetates; Salicylic acids; Small molecules
- Mechanism of Action Cyclooxygenase inhibitors; Nitric oxide stimulants; Platelet aggregation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Suspended Musculoskeletal pain
- Discontinued Cardiovascular disorders
Most Recent Events
- 27 Sep 2017 Suspended for Musculoskeletal pain in United Kingdom, pending conclusion of a strategic review (PO)
- 09 Nov 2016 Discontinued for OXPzero™ aspirin programme for Cardiovascular disorders in United Kingdom (PO)
- 02 Jul 2015 Early research in Cardiovascular disorders in United Kingdom (PO) prior to July 2015